HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: dc07-1992v1 31/5/852    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yang, W. Articles by Yan, L. Search for Related Content PubMed PubMed Citation Articles by Yang, W. Articles by Yan, L. Social Bookmarking                What's this?

Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on OADs

¹China-Japan Friendship Hospital, Dept. Endocrinology, Beijing, China
²The Xijing Hospital affiliated to 4th Military Medical University, Dept. Endocrinology, Xi'an, China
³The Nanjing Drum Tower Hospital, Dept. Endocrinology, Nanjing, China
⁴The Beijing Tongren Hospital, Dept. Endocrinology, Beijing, China
⁵The Wuhan Union Hospital, Dept. Endocrinology, Wuhan, China
⁶The Shanghai Changzheng Hospital, Dept. Endocrinology, Shanghai, China
⁷The Metabolic Disease Hospital affiliated to Tianjin Medical University, Dept. Endocrinology, Tianjin, China
⁸Sun Yixian Commemorative Hospital affiliated to Zhongshan University, Dept. Endocrinology, Guangzhou, China

yangwenying1707{at}yahoo.com.cn

yangwenying1707{at}yahoo.com.cn

ABSTRACT

Objective: To assess efficacy and safety of twice- (BID) and three-times daily (TID) biphasic insulin aspart 30 (BIAsp 30) in Chinese subjects with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs).

Research Design and Methods: In this 24-week, multicenter, parallel-group, randomized, treat-to-target study, 321 Chinese insulin-naïve subjects with poorly-controlled type 2 diabetes (fasting blood glucose [FBG] 7.8 mmol/l; HbA_1c 7.5%) were randomized (1:1) to BID or TID BIAsp 30 without OADs. Initial insulin doses were based on FBG at randomization. Insulin dose was adjusted with algorithm-controlled titration to achieve pre-meal BG of 4.4–6.1 mmol/L.

Results: HbA_1c decreased significantly in both groups (BID: –2.48±0.07%; TID: –2.81±0.07%). TID BIAsp 30 showed superiority in HbA_1c improvement (–0.33%, 95% CI (–0.53; –0.13), P<0.01) and helped more subjects achieve HbA_1c targets <7% (BID: 51.3% vs. TID: 65.8%, P<0.01). TID BIAsp 30 was more effective in subjects with HbA_1c baseline 9% (<7%: BID: 41.5% vs. TID: 58.3%, P<0.01). There was no significant difference in rates of overall and nocturnal major and minor hypoglycemia per subject year between groups. No significant differences in weight gain (BID: 3.87±0.28 kg; TID: 4.09±0.27 kg) and mean daily insulin doses (BID: 0.82±0.28 U/kg; TID: 0.86±0.34 U/kg) were observed.

Conclusions: BID and TID BIAsp 30 were effective in Chinese insulin-naïve subjects with poorly controlled type 2 diabetes. TID BIAsp 30 offered greater reduction in HbA_1c without increasing risk of hypoglycemia, insulin dose and weight gain, especially in subjects with HbA_1c 9%.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?